Table 3.
Characteristics of outcomes, drug intake, and general diseases and the main results from included studies.
| Outcomes | Author, Year | Drug Intake and General Diseases | Main Result |
|---|---|---|---|
| Osseointegration | Aghaloo (2019) [36] | ARDs | No differences in patients with or without osteoporosis with antiresorptive therapy. |
| Diabetes | No differences were seen among diabetic and healthy patients. | ||
| Luo et al. (2018) [39] | NSAIDs | Could not be adequately estimated. | |
| Werny et al. (2022) [43] | Vitamin D | There was slight evidence that vitamin D supplementation improves implant osseointegration in humans. | |
| Implant survival rate | Aghaloo et al. (2019) [36] | Osteoporosis | The pooled estimated was 98% (with a confidence interval of 95%). |
| Neurologic disorder | The implant survival rate was 86%. | ||
| Papadakis et al. (2023) [41] | ARDs | Antiresorptive medication did not reduce the success rate of dental implants or implant survival rates. | |
| Chappuis et al. (2018) [37] | Anti-hypertensive, diuretics, or beta blockers | The analysis could not be performed. | |
| Implant loss rate | Stavropoulos et al. (2018) [42] | ARDs | No differences in patients with or without osteoporosis with antiresorptive therapy. |
| HRT | HRT intake studies reported a higher implant loss rate (9.1–27.3%) compared to controls (7.4–16.1%). | ||
| Implant success rate | Papadakis et al. (2023) [41] | ARDs | ARDs did not reduce the success rate of dental implants or implant survival rates. |
| Implant failure rate | Chappuis et al. (2018) [37] | ARDs | No differences in patients with or without osteoporosis with antiresorptive therapy. |
| Anti-hypertensive, diuretics, or beta blockers | The analysis could not be performed. | ||
| SSRIs | It seems that the test (SSRI intake) group had a significantly higher risk than the control group. | ||
| PPIs | Implant failure rates were higher in the test group compared to the control group (p < 0.01). | ||
| Aghaloo et al. (2019) [36] | HIV | A 0.8% failure rate compared to 100% failure in non-HIV patients. | |
| Cardiovascular disease | No statistically significant differences were found among test and control groups. | ||
| Hypothyroidism | No differences were found among healthy and diseased patients. | ||
| Anti-hypertensive, diuretics, or beta blockers | In patients who took medication, implant survival rate was 99.4% versus 95.9% in patients not taking these medications. | ||
| SSRIs | A lower implant survival rate of 89.4% to 94.4% vs. 95.4% to 98.15% in patients not taking these drugs was shown. | ||
| PPIs | PPI users had an increased implant failure rate of 12% to 6.8% vs. 4.5% to 3.2% in PPI non-users. | ||
| Bone marginal loss | Fiorillo et al. (2022) [38] | ARDs | No differences in patients with or without osteoporosis with antiresorptive therapy. |
| Peri-implant mucositis or peri-implantitis | Monje et al. (2017) [40] | Diabetes | The risk of peri-implantitis in hyperglycemic subjects was statistically significantly higher than normoglycemic subjects. |
Abbreviations: NSAIDs—non-steroidal anti-inflammatory drugs; SSRIs—serotonin reuptake inhibitors; PPIs—proton-pump inhibitors; ARDs—antiresorptive drugs; HIV—human immunodeficiency virus; HRT—hormone replacement therapy.